<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00622752</url>
  </required_header>
  <id_info>
    <org_study_id>EVT 302/3011</org_study_id>
    <secondary_id>EUDRACT No.: 2007-006236-63</secondary_id>
    <nct_id>NCT00622752</nct_id>
  </id_info>
  <brief_title>Effects of EVT 302 With or Without NRT on Craving and Withdrawal in Healthy Male Smokers Deprived of Cigarettes</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo- and NRT -Controlled Phase II Study to Assess the Effects of EVT 302 Alone and in Combination With NRT on Craving and Withdrawal in Healthy Male Smokers Deprived of Cigarettes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evotec Neurosciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Evotec Neurosciences GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomised, placebo-controlled study is designed to explore the effects of EVT 302 both
      with and without concomitant nicotine replacement therapy (NRT) on craving and withdrawal in
      smokers after short term deprivation of cigarettes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Craving and withdrawal</measure>
    <time_frame>Within 12 hours of the last cigarette</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CogState Cognitive test Battery</measure>
    <time_frame>12 hours post last cigarette</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breath carbon monoxide levels</measure>
    <time_frame>12 hours post last cigarette</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary cotinine levels</measure>
    <time_frame>12 hours post last cigarette</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical safety lab tests</measure>
    <time_frame>Up to 7 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of adverse events</measure>
    <time_frame>Up to 7 days post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EVT 302, 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EVT 302, 10 mg + NRT patch, 21 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NRT patch, 21 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match EVT 302 and placebo patch to match NRT patch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EVT 302, 10 mg</intervention_name>
    <description>2 X EVT 302, 5 mg tablets</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>2 X placebo tablets to match EVT 302 5 mg</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine replacement therapy (NRT)</intervention_name>
    <description>NRT patch containing 21 mg of nicotine</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NRT placebo</intervention_name>
    <description>Medically inert plaster cut to match the NRT plaster</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subjects between 18 and 55 years of age, inclusive

          -  BMI between 18 and 30, minimum weight of 50 kg

          -  Negative urine drug &amp; alcohol screen

          -  Able to comply with tyramine-restricted diet

          -  Smoking of ≥17 and ≤34 cigarettes per day for the past year and have not tried to quit
             smoking in the 3 months prior to screening

          -  Subjects are willing and able to quit for about 12 hours in each of three subsequent
             study periods

          -  Previous experience of craving following smoking cessation

          -  Breath CO between 15 ppm and 20 ppm and cotinine in saliva and plasma at least 250
             ng/mL at screening

          -  Liver function test results not above 1.5 times the upper normal limit (UNL) at
             screening visit and at re-assessment during the study.

        Exclusion Criteria:

          -  Participation in another clinical study within 60 days of screening

          -  Evidence of active significant psychiatric or neurological disease or dependency other
             than cigarettes

          -  Are known to have or are a carrier of the hepatitis B surface antigen (HBsAg),
             hepatitis C virus (HCV) antibody, has a positive result to the human immunodeficiency
             virus-1 and/or 2 (HIV-1 and/or HIV-2) antibodies

          -  Known hypersensitivity to MAO inhibitors or any substance that is contained in the
             study formulations

          -  Known allergy to plasters or NRT patches

          -  Previous participation in another study with EVT 302

          -  Currently receiving treatment for smoking cessation

          -  Current use of tobacco products other than cigarettes

          -  Require treatment with any medication

          -  Subject with a clinically relevant abnormal 12-lead ECG recording or QTcB/F &gt;430 ms

          -  Use of a prescription medicine within 14 days or 5 half-lives, whichever is the
             longer, of the start of dosing, or use of an over-the-counter medication during the 7
             days before the study, including herbal remedies, but excluding paracetamol and
             vitamin supplements (provided intake does not exceed the daily recommended allowance)

          -  Subjects must not be planning to father a child or donate sperm, during the study and
             3 months after the end of the study. Acceptable methods of contraception comprise
             barrier contraception and a medically accepted contraceptive method for the female
             partner (intra-uterine device with spermicide, hormonal contraceptive since at least 2
             month)

          -  Daily consumption of more than 5 cups of tea or coffee, or more than 1.0 litre of
             xanthine-containing drinks

          -  Recent myocardial infarction, unstable or worsening angina pectoris, prince metal
             angina, severe arrhythmias, recent stroke.

          -  Creatinine clearance (CLR) calculated according to the formula by Modification of Diet
             in Renal Disease (MDRD) of &lt;80 mL/min
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alla Radicke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel International GmbH, Clinical Pharmacology Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PAREXEL International GmbH, Clinical Pharmacology Research Unit</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2008</study_first_submitted>
  <study_first_submitted_qc>February 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2008</study_first_posted>
  <last_update_submitted>June 16, 2008</last_update_submitted>
  <last_update_submitted_qc>June 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>Doris Greiling, Clinical Development Programme Manager</name_title>
    <organization>Evotec Neurosciences GmbH</organization>
  </responsible_party>
  <keyword>Smoking cessation</keyword>
  <keyword>Craving</keyword>
  <keyword>Smokers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

